Key result
Periprocedural MI remains a frequent complication despite PCI being an established chronic coronary syndrome treatment.
Why the study?
Periprocedural MI remains a frequent complication following PCI in patients with CCS, potentially offsetting the benefits of revascularization.
Should not yet change post-PCI care in chronic coronary syndrome; hypothesis-generating for symptom monitoring and periprocedural risk reduction.
Percutaneous coronary intervention (PCI) is an established treatment for patients with chronic coronary syndrome (CCS) providing angina relief and a reduced risk of spontaneous ischemic events compared to medical therapy.1 Despite technical and pharmacological advancements, periprocedural myocardial infarction (MI) remains a frequent complication, potentially offsetting the benefits of revascularization.2 Based on the fourth universal definition of MI (UDMI), periprocedural MI requires troponin elevation after PCI with ≥1 ancillary criterion between ECG, imaging, or angiographic criteria.
No takes yet. Share an insight, caveat, or question.
Piccolo et al. (2025) studied chronic coronary syndrome (CCS). Percutaneous coronary intervention (PCI) vs. medical therapy was evaluated. Percutaneous coronary intervention is an established treatment for chronic coronary syndrome, though periprocedural myocardial infarction remains a frequent complication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: